Diabetes has become one of the most urgent health challenges of our time. Today, over 589 million adults around the world live with this chronic metabolic condition — a number expected to surge to 853 million by 2050*. Diabetes is one of the most urgent health challenges of our time, affecting hundreds of millions worldwide and placing immense strain on patients, families and healthcare systems. As a credible, global player in the area of diabetes, Biocon is committed to making therapies for diabetes management increasingly affordable and accessible across the globe.
CONTACT
Group Companies
KEY THERAPEUTIC AREAS
Diabetes
Biosimilars
Since 2004, when Biocon Biologics became the first company in the world to develop a biosimilar recombinant human insulin using a proprietary Pichia pastoris platform, the company has played a pivotal role for patients with diabetes, as well as their caregivers and physicians, charting a path to affordable and accessible insulin that others continue to follow.
Our expertise in pioneering affordable insulins and biosimilars has led to industry firsts—including the first interchangeable Insulin Glargine biosimilar, followed by the first and only interchangeable rapid-acting Insulin Aspart approved in the U.S.
Through cutting-edge science, advanced manufacturing, and strong global partnerships, we are expanding access to high-quality, affordable insulins for patients who need them most.
Novel Biologics
Insulin Tregopil
Insulin Tregopil, a first-in-class oral insulin molecule being developed by Biocon, is one of the most advanced programs in the global oral insulin space. It has completed a Phase II study in Type 2 diabetes patients in India.
Insulin Tregopil is undergoing a multiple ascending dose study in Type 1 diabetes patients in Germany, in partnership with the U.S.-based JDRF, a leading global organisation funding Type 1 diabetes research and advocacy worldwide.
Generics
Biocon offers a strong portfolio of generic APIs for diabetes that include:
- Vildagliptin
- Linagliptin
- Sitagliptin (various salts)
- Dapagliflozin (different solvate forms)
- Empagliflozin
- Repaglinide
- Liraglutide
- Semaglutide
The leader in Insulins
1st company globally to develop rh-insulin using a proprietary yeast platform based on Pichia pastoris.
1st company from India to get approval for and commercialise biosimilar Insulin Glargine in Japan.
1st company from India to commercialise biosimilar Insulin Glargine in Australia through the Pharmaceutical Benefits Scheme (PBS).
WHO WE ARE
PRESS RELEASES
